Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment

• US 5,795,563 A
• Filed: 12/13/1996
• Issued: 08/18/1998
• Est. Priority Date: 09/04/1996
• Status: Expired due to Term

• Current Assignee: Sphingomanas Research Partners LP
• Original Assignee: Sphingomanas Research Partners LP
• Inventors: Kallick, Charles A.
• Primary Examiner(s): Weddington, Kevin E.
• Application Number:
  US08/763,709
• Time in Patent Office: 613 Days
• Field of Search: 424/2, 424/3, 424/9.361, 424/9.362, 424/9.363, 514/192, 514/199, 514/200
• US Class Current: 424/9.361
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/545 Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins, cefaclor, or cephalexine
• CPC Class Codes: A61K 49/006 Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery

Abstract

Intra-erythrocytic exogenous bacterial structures or parasites seen by giemsa and phase contrast microscopy in several patients with systemic lupus erythematosus (SLE) and not in controls were identified as bacteria. Treatment of an SLE patient is contemplated with an antibacterial amount of a rifamycin in conjunction with an antibacterial amount of either a macrolide such as clarithromycin or a third generation cephalosporin such as cefpodoxime that is itself more preferably used in conjunction with an adjuvant amount of probenecid.

Claims

1. A process for treating a patient whose erythrocytes contain exogenous bacterial structures stainable with acridine orange or giemsa and are visible in phase contrast microscopy that comprises administering to said patient an antibacterial amount of a rifamycin plus an antibacterial amount of a macrolide or a third generation cephalosporin until said exogenous bacterial structures are absent from the erythrocytes.

2. The process according to claim 1 wherein a third generation cephalosporin is administered and an adjuvant amount of probenecid is administered in conjunction with said administration of said third generation cephalosporin and a rifamycin.

3. The process according to claim 1 wherein a rifamycin and a macrolide are administered.

4. The process according to claim 1 wherein said administration is repeated periodically.

5. The process according to claim 1 wherein said rifamycin is rifampin or rifabutin.